Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials (original) (raw)

• Kaspers GJL, Creutzig U . Pediatric acute myeloid leukemia: international progress and future directions. Leukemia 2005; 19: 2025–2029.
  Article CAS PubMed Google Scholar
• Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030–2042.
  Article CAS PubMed Google Scholar
• Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Benard A, Bordigoni P et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. J Clin Oncol 2003; 21: 4377–4385.
  Article CAS PubMed Google Scholar
• Rubnitz JE, Razzouk BI, Lensing S, Pounds S, Pui CH, Ribeiro RC . Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia. Cancer 2007; 109: 157–163.
  Article PubMed Google Scholar
• Stahnke K, Boos J, Bender-Gotze C, Ritter J, Zimmermann M, Creutzig U . Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 1998; 12: 1534–1538.
  Article CAS PubMed Google Scholar
• Webb DKH, Wheatley K, Harrison G, Stevens RF, Hann IM . Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. Leukemia 1999; 13: 25–31.
  Article CAS PubMed Google Scholar
• Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–2333.
  CAS PubMed Google Scholar
• Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol 1999; 107: 69–79.
  Article CAS PubMed Google Scholar
• Abrahamsson J, Clausen N, Gustafsson G, Hovi L, Jonmundsson G, Zeller B et al. Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol 2007; 136: 229–236.
  Article PubMed Google Scholar
• Creutzig U, Ritter J, Zimmermann M, Schellong G . Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87. J Clin Oncol 1993; 11: 279–286.
  Article CAS PubMed Google Scholar
• Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt- Munster 93. J Clin Oncol 2001; 19: 2705–2713.
  Article CAS PubMed Google Scholar
• Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030–2042.
  Article CAS PubMed Google Scholar
• Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006; 24: 4499–4506.
  Article CAS PubMed Google Scholar
• Reinhardt D, Hempel G, Fleischhack G, Schulz A, Boos J, Creutzig U . Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children]. Klin Padiatr 2002; 214: 188–194.
  Article CAS PubMed Google Scholar
• Fleischhack G, Hasan C, Graf N, Mann G, Bode U . IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol 1998; 102: 647–655.
  Article CAS PubMed Google Scholar
• Kaplan EL, Meier P . Nonparametric-estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
  Article Google Scholar
• Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Löffler H et al. Definition of a standard-risk group in children with AML. Br J Haematol 1999; 104: 630–639.
  Article CAS PubMed Google Scholar
• Webb DK, Harrison G, Stevens RF, Gibson BG, Hann IM, Wheatley K . Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001; 98: 1714–1720.
  Article CAS PubMed Google Scholar
• Goemans BF, Tamminga RY, Corbijn CM, Hahlen K, Kaspers GJ . Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only? Haematologica 2008; 93: 1418–1420.
  Article PubMed Google Scholar
• Fagioli F, Zecca M, Locatelli F, Lanino E, Uderzo C, Di Bartolomeo P et al. Allogeneic stem cell transplantation for children with acute myeloid leukemia in second complete remission. J Pediatr Hematol Oncol 2008; 30: 575–583.
  Article PubMed Google Scholar
• Gassas A, Ishaqi MK, Afzal S, Finkelstein-Shechter T, Dupuis A, Doyle J . A comparison of the outcomes of children with acute myelogenous leukemia in either first or second complete remission (CR1 vs CR2) following allogeneic hematopoietic stem cell transplantation at a single transplant center. Bone Marrow Transplant 2008; 41: 941–945.
  Article CAS PubMed Google Scholar
• Godder K, Eapen M, Laver JH, Zhang MJ, Camitta BM, Wayne AS et al. Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis. J Clin Oncol 2004; 22: 3798–3804.
  Article PubMed Google Scholar
• Shaw BE, Russell NH . Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant 2008; 41: 495–503.
  Article CAS PubMed Google Scholar
• Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405–412.
  Article CAS PubMed Google Scholar
• Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA et al. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant 2006; 12: 414–421.
  Article PubMed Google Scholar
• Arellano ML, Langston A, Winton E, Flowers CR, Waller EK . Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 2007; 13: 116–123.
  Article PubMed Google Scholar
• Michallet M, Tanguy ML, Socie G, Thiebaut A, Belhabri A, Milpied N et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol 2000; 108: 400–407.
  Article CAS PubMed Google Scholar